These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 810417)

  • 1. Characteristics of the effector cells mediating cytotoxicity against antibody-coated target cells. I. Phagocytic and non-phagocytic effector cell activity against erythrocyte and tumour target cells in a 51Cr release cytotoxicity assay and [125I]IUdR growth inhibition assay.
    Greenberg AH; Shen L; Medley G
    Immunology; 1975 Oct; 29(4):719-29. PubMed ID: 810417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-dependent cell-mediated cytotoxicity. Comparative ability of murine Peyer's patch and spleen cells to lyse lipopolysaccharide-coated and uncoated erythrocytes.
    Kagnoff MF; Campbell S
    Gastroenterology; 1976 Mar; 70(3):341-6. PubMed ID: 1082425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The nature of the K cell and the role of antibody-dependent cell mediated cytotoxicity (ADCC) in the rejection of tumours.
    Greenberg AH; Wolosin LB
    Ann Immunol (Paris); 1977; 128(1-2):485-91. PubMed ID: 848900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Separation of effector cells mediating antibody-dependent cellular cytotoxicity (ADC) to erythrocyte targets from those mediating ADC to tumor targets.
    Pollack SB; Nelson K; Grausz JD
    J Immunol; 1976 Apr; 116(4):944-6. PubMed ID: 815438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mouse effector functions involved in the antibody-dependent cellular cytotoxicity to xenogeneic erythrocytes.
    Cohen SA; Ehrke MJ; Mihich E
    J Immunol; 1975 Oct; 115(4):1007-12. PubMed ID: 1100718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of the effector cells mediating cytotoxicity against antibody-coated target cells. II. The mouse nonadherent K cell.
    Greenberg AH; Shen L; Walker L; Arnaiz-Villena A; Roitt IM
    Eur J Immunol; 1976 Jul; 5(7):474-80. PubMed ID: 976311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allograft cytotoxicity. Two populations of effector cell detectable by cytolytic and cytostatic assays in vitro.
    Jones B; Jones TC; Roitt IM
    Immunology; 1977 Apr; 32(4):591-9. PubMed ID: 415967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effector cells in avian spontaneous and antibody-dependent cell-mediated cytotoxicity.
    Fleischer B
    J Immunol; 1980 Sep; 125(3):1161-6. PubMed ID: 7410832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of the effector cells mediating cytotoxicity against antibody-coated target cells. III. Ultrastructural studies.
    Penfold PL; Greenberg AH; Roitt IM
    Clin Exp Immunol; 1976 Jan; 23(1):91-7. PubMed ID: 1261093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2.
    Hinuma S; Naruo K; Shiho O; Tsukamoto K
    Immunology; 1986 Oct; 59(2):251-9. PubMed ID: 3490435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
    Fuyama S; Yamamoto H; Fujii Y; Arai S
    Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effector cells in human peripheral blood mediating mitogen-induced cellular cytotoxicity and antibody-dependent cellular cytotoxicity.
    Nelson DL; Bundy BM; Pitchon HE; Blaese RM; Strober W
    J Immunol; 1976 Nov; 117(5 Pt 1):1472-81. PubMed ID: 1087314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reticulum cell sarcoma: an effector cell in antibody-dependent cell-mediated immunity.
    Ralph P; Prichard J; Cohn M
    J Immunol; 1975 Feb; 114(2 pt 2):898-905. PubMed ID: 1089721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IgM antibody-dependent cell-mediated cytotoxicity in the Moloney sarcoma virus system: the involvement of T and B lymphocytes as effector cells.
    Lamon EW; Whitten HD; Skurzak HM; Andersson B; Lidin B
    J Immunol; 1975 Nov; 115(5):1288-94. PubMed ID: 1080777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific and nonspecific antitumor immunity. I. Description of an in vitro assay based on inhibition of DNA synthesis in tumor cells.
    Williams RM; Germain RN; Benacerraf B
    J Natl Cancer Inst; 1975 Mar; 54(3):697-708. PubMed ID: 1091740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of specific and non-specific tumour immunity after azathioprine treatment of mice.
    Purves EC
    Clin Exp Immunol; 1975 Nov; 22(2):348-58. PubMed ID: 813934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of immune effector cell cytolytic activity and tumour growth inhibition in vivo by Ukrain (NSC 631570).
    Liepins A; Nowicky JW
    Drugs Exp Clin Res; 1996; 22(3-5):103-13. PubMed ID: 8899312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of SV40 tumor-mediated suppression of spleen cell cytotoxicity by antibody.
    Prather SO; Lausch RN
    J Immunol; 1977 Jan; 118(1):203-10. PubMed ID: 187698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective blocking of T cell-mediated in vitro cytotoxicity to a xenogeneic tumour by anti-immunoglobulin sera.
    Newlands ES; Hay FC; Roitt IM
    Clin Exp Immunol; 1978 Feb; 31(2):189-96. PubMed ID: 306324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural cytotoxicity against mouse hepatitis virus-infected target cells. I. Correlation of cytotoxicity with virus binding to leukocytes.
    Holmes KV; Welsh RM; Haspel MV
    J Immunol; 1986 Feb; 136(4):1446-53. PubMed ID: 3003198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.